Skip to main content
Top

Open Access 27-06-2025 | Multiple Myeloma | Case Report

Effectiveness of venetoclax based therapy in t(11;14) multiple myeloma with extensive extramedullary disease: a case report

Authors: Kerstin Brinkert, Bernd Heinrich, Annamaria Brioli, Michael Heuser, Hans Heinrich Kreipe, Florian H. Heidel, Arnold Ganser, Gernot Beutel

Published in: Annals of Hematology

Login to get access

Abstract

Extramedullary disease in patients with newly diagnosed multiple myeloma is rare and, despite the abundance of new therapeutic options, is still associated with a dismal prognosis, classifying as an unmet clinical need. Here, we report the case of a young woman diagnosed with multiple myeloma and extensive extramedullary disease characterised by diffuse lymph node involvement. The patient received multiple chemotherapy regimens proving to be refractory to all of them and ultimately benefited from salvage therapy with Venetoclax combination therapy, with a complete disappearance of the extramedullary manifestations. This case proves the effectiveness of Venetoclax in t(11;14) myeloma with extramedullary involvement.
Literature
This content is only visible if you are logged in and have the appropriate permissions.
Metadata
Title
Effectiveness of venetoclax based therapy in t(11;14) multiple myeloma with extensive extramedullary disease: a case report
Authors
Kerstin Brinkert
Bernd Heinrich
Annamaria Brioli
Michael Heuser
Hans Heinrich Kreipe
Florian H. Heidel
Arnold Ganser
Gernot Beutel
Publication date
27-06-2025
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-025-06489-6

ASCO 2025 Annual Meeting

Keep up to date with the latest in oncology research with our ASCO 2025 hub page, featuring official videos, breaking news, and more.

Read more

Innovations in AML: insights and practical guidance

Hear directly from acute myeloid leukemia experts in this vodcast series focussing on innovations in molecular testing, emerging therapies, and targeted treatments, and get practical advice for improving the care of your patients with relapsed or refractory disease.

Supported by:
  • Rigel Pharmaceuticals, Inc.
Developed by: Springer Health+ IME
Learn more
SPONSORED

Masterclass webinar: Expert review of CAR T-cell therapy patient cases in R/R DLBCL or R/R FL

  • Live
  • Webinar | 29-07-2025 | 09:00 (CEST)

Professor Joy Ho leads a panel of Asia-Pacific-based experts, exchanging their practical experiences of identifying appropriate patients for CAR T-cell therapy, aspects of pre- and post-infusion management, and treatment sequencing, and sharing insights into optimizing outcomes in R/R DLBCL or R/R FL. 

This educational activity is intended for an audience of non-US, non-UK and on-label Asia Pacific healthcare professionals.

Watch it live: Tuesday 29th July, 09:00-10:30 (CEST)

Sponsored by:
  • Novartis Pharma AG
Prof. Joy Ho
Dr. Kentaro Fukushima
Prof. William Hwang
Prof. Dok Hyun Yoon
Prof. Miki Ando
Developed by: Springer Health+
Join the webinar
Webinar